The Foundation for Sarcoidosis Research (FSR), the leading international nonprofit organization dedicated to finding a cure and improving care for sarcoidosis patients, conducted a two-day training of patient volunteer leaders to collaborate with and support the FSR...
Foundation for Sarcoidosis Research (FSR) has been named an Official Charity Partner for the 2023 TCS New York City Marathon, which takes place on Sunday, November 5. FSR will be among more than 550 official charity partners providing thousands of runners the...
The Foundation for Sarcoidosis Research (FSR), the leading international nonprofit organization dedicated to finding a cure and improving care for sarcoidosis patients, announces FSR’s Inaugural Sarcoidosis Crystal Awards Gala: Celebrating Connections, Collaboration,...
aTyr Pharma, Inc. is partnering with the Foundation for Sarcoidosis Research (FSR) to recruit for a global pivotal Phase 3 study, EFZO-FIT™, of aTyr’s lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis. This study comes on...
The Foundation for Sarcoidosis Research (FSR) is pleased to award Dr. Nabeel Hamzeh, Professor of Internal Medicine – Pulmonary, Critical Care and Occupational Medicine at The University of Iowa, funding for cardiac sarcoidosis research in the amount...
“My hope is that this campaign will greatly increase awareness of sarcoidosis and encourage Black patients to participate in clinical trials. That will ultimately improve our lives and benefit everyone in the sarcoidosis community.” Calvin Harris FSR Patient...
FSR is proud to announce the launch of the Ignore No More: ACTe Now! (Advance Clinical Trials for Equity in Sarcoidosis) campaign. The goals of this campaign are to increase representation of Black American sarcoidosis patients in clinical trials, raise awareness of...
FSR is pleased to announce that the FSR Sarcoidosis Research Fellowship for 2022-2024 is being awarded to Dr. Nancy Lin from National Jewish Health, a Founding Member of the FSR Global Sarcoidosis Clinic Alliance, for her project, “Defining MicroRNA Biomarkers...
On April 21, 2022, The Foundation for Sarcoidosis Research (FSR) hosted a virtual Patient Listening Session on Pulmonary Sarcoidosis with the US Food and Drug Administration (FDA). FDA Patient Listening Sessions are small, informal, non-regulatory, non-public...
FSR is pleased to announce the appointment of Michael Klingher to the FSR Board of Directors. Klingher has over 35 years’ experience as an investment banker and investor in commercial real estate, working with Goldman Sachs and in managing his own real estate...
